Virginia Cancer Specialists | Association Partnerships

Latest from Virginia Cancer Specialists


Experts Anticipate New Results From Sotorasib for KRAS G12C+ NSCLC

July 14, 2022

A highly anticipated presentation at the 2022 World Conference on Lung Cancer will be the first report of efficacy and safety from the phase 1b/2 CodeBreak 101 clinical trial and will provide updated results from the phase 2 CodeBreak 100 study.

The Safety Profile of Amivantamab and Lazertinib in EGFR-Mutant NSCLC

June 06, 2021

Alexander Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, discusses the safety profile of amivantamab and lazertinib in EGFR-mutated non-small cell lung cancer, based on data from the CHRYSALIS tria.

Targeted Oncology™ Adds Two New Premier Oncology Association Partners to Its Strategic Alliance Partnership Program

March 16, 2021

Targeted Oncology™ is excited to announce it has expanded its Strategic Alliance Partnership program with the addition of the Kentucky Society of Clinical Oncology and Virginia Cancer Specialists, strengthening its position in the oncology space.